Investment firm SEMCAP has launched a new Beauty & Wellness vertical, a move that coincides with L’Oréal-owned Lancôme's unveiling of a new longevity skincare line and underscores a significant industry pivot toward health and science.

These parallel developments highlight a strategic convergence of beauty, wellness, and biotechnology. As consumers increasingly prioritize preventative health and science-backed solutions, major beauty brands are reformulating their product pipelines and marketing to address the drivers of aging, not just its visible symptoms. This shift is attracting significant new investment, as seen with the SEMCAP launch, signaling a structural and potentially recession-resistant evolution in a global market estimated at $6.8 trillion, according to Global Cosmetics News.

What We Know So Far

  • Investment management firm SEMCAP has officially launched SEMCAP Beauty & Wellness, a new vertical aimed at high-growth brands and technologies.
  • Vasiliki Petrou, the founder of Unilever Prestige and a former Procter & Gamble executive, has been appointed to lead the new SEMCAP strategy.
  • L’Oréal-owned beauty brand Lancôme has introduced a new five-product anti-aging collection named Absolute Longevity MD, according to a report from Athletech News.
  • As part of its new initiative, Lancôme has partnered with Korean bio-tech firm NanoEntek to develop Cell BioPrint, a diagnostic tool that analyzes five skin-surface biomarkers to offer personalized routines.
  • The new SEMCAP vertical will focus on making majority or significant minority investments in companies across North America and Europe in sectors including skincare, cosmetics, and personalized health.
  • Other luxury players are also entering the space; Dior recently introduced a new longevity skincare product called L’Or de Vie Le Grand Cérémonial Millésime 2024, as reported by Modern Luxury.

Lancôme's Longevity Skincare: Key Initiatives Explained

Lancôme launched its Absolute Longevity MD line, a five-product biotech system priced from $155 to $175, designed to address skin health at a cellular level. Detailed by Glossy, this move positions the legacy brand in longevity science, reflecting parent company L’Oréal’s prior $66 million Series D investment in consumer health biotech company Timeline.